Valdecoxib: What a Diaryl Isoxazole Reveals About COX-2 Selectivity

Cyclooxygenase isoforms COX-1 and COX-2 contribute to prostaglandin synthesis. COX-1 supports functions such as gastric mucosal protection; COX-2 is often induced during inflammation but also has physiological roles. Coxibs were developed to favor COX-2 inhibition, reducing interference with COX-1. Valdecoxib illustrates how molecular design can produce this preference.

Reading the Molecule

Valdecoxib, also called SC-65872, is 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide. Its formula is C16H14N2O3S, and its molecular weight is approximately 314.4 g/mol.

The Valdecoxib chemical structure places two aromatic groups on adjacent carbons of an isoxazole ring, which also carries a methyl group. One aromatic ring bears a sulfonamide. This polar group is a key selectivity feature: it accesses a side pocket that is more readily available in COX-2 than in COX-1. The scaffold positions the substituents for these interactions, so selectivity cannot be assigned to the sulfonamide alone.

Measured Selectivity

The compound was described in the Journal of Medicinal Chemistry in 2000. Reported activity values include:

  • human recombinant COX-2: IC50 of 0.005 µM;
  • human recombinant COX-1: IC50 of 140 µM;
  • LPS-induced PGE2 production in human whole blood: IC50 of 0.89 µM.

The recombinant-enzyme values give a roughly 28,000-fold ratio under those assay conditions. This is not a universal selectivity value. Whole-blood assays measure prostaglandin production in a cellular, protein-containing environment, where protein binding and other protocol differences affect apparent potency. The blood result should therefore be interpreted separately from the enzyme measurements.

Activity in Rat Models

Reported oral ED50 values were 10.2 mg/kg for carrageenan-induced paw edema and 0.032 mg/kg/day for adjuvant-induced arthritis. The daily-dose unit matters when comparing these results.

The models differ in disease course, dosing schedule and measured outcome. Their ED50 values describe responses within each experiment; the difference alone does not explain which biological factor accounts for the greater apparent potency in arthritis.

Market History and Current Research Use

Valdecoxib was marketed as Bextra. Parecoxib, its prodrug, was developed for injectable administration. Bextra was withdrawn from the US market in 2005 following concerns about cardiovascular risk and serious skin reactions.

In research, valdecoxib provides a reference for COX isoform assays, prostaglandin studies and comparisons between coxib scaffolds. Reported solubility is about 20 mg/mL in DMSO or DMF and 5 mg/mL in ethanol, with poor aqueous solubility. These figures describe specific preparation conditions; stock concentration and compatibility with the final assay medium require verification.

Enjoyed this article? Share it!

Zalven Draxen
Written By

Zalven Draxen

2081 Articles

Zalven is a U.S.-based SEO strategist and digital marketing expert known for helping businesses grow through search optimization, online visibility, and smart content strategies. With deep experience in technical SEO and local search, he simplifies complex marketing concepts into clear, actionable insights for brands of all sizes.